These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Structural properties for selective and efficient l-type amino acid transporter 1 (LAT1) mediated cellular uptake. Kärkkäinen J; Gynther M; Kokkola T; Petsalo A; Auriola S; Lahtela-Kakkonen M; Laine K; Rautio J; Huttunen KM Int J Pharm; 2018 Jun; 544(1):91-99. PubMed ID: 29669256 [TBL] [Abstract][Full Text] [Related]
3. Insights into the Structure, Function, and Ligand Discovery of the Large Neutral Amino Acid Transporter 1, LAT1. Singh N; Ecker GF Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29695141 [TBL] [Abstract][Full Text] [Related]
4. Comparison of Experimental Strategies to Study l-Type Amino Acid Transporter 1 (LAT1) Utilization by Ligands. Huttunen J; Agami M; Tampio J; Montaser AB; Huttunen KM Molecules; 2021 Dec; 27(1):. PubMed ID: 35011270 [TBL] [Abstract][Full Text] [Related]
5. Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Kim DK; Kanai Y; Choi HW; Tangtrongsup S; Chairoungdua A; Babu E; Tachampa K; Anzai N; Iribe Y; Endou H Biochim Biophys Acta; 2002 Sep; 1565(1):112-21. PubMed ID: 12225859 [TBL] [Abstract][Full Text] [Related]
6. Rigorous sampling of docking poses unveils binding hypothesis for the halogenated ligands of L-type Amino acid Transporter 1 (LAT1). Singh N; Villoutreix BO; Ecker GF Sci Rep; 2019 Oct; 9(1):15061. PubMed ID: 31636293 [TBL] [Abstract][Full Text] [Related]
7. Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1). Chien HC; Colas C; Finke K; Springer S; Stoner L; Zur AA; Venteicher B; Campbell J; Hall C; Flint A; Augustyn E; Hernandez C; Heeren N; Hansen L; Anthony A; Bauer J; Fotiadis D; Schlessinger A; Giacomini KM; Thomas AA J Med Chem; 2018 Aug; 61(16):7358-7373. PubMed ID: 30048132 [TBL] [Abstract][Full Text] [Related]
8. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Uchino H; Kanai Y; Kim DK; Wempe MF; Chairoungdua A; Morimoto E; Anders MW; Endou H Mol Pharmacol; 2002 Apr; 61(4):729-37. PubMed ID: 11901210 [TBL] [Abstract][Full Text] [Related]
9. Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug. Thiele NA; Kärkkäinen J; Sloan KB; Rautio J; Huttunen KM Bioorg Med Chem Lett; 2018 Sep; 28(17):2856-2860. PubMed ID: 30055889 [TBL] [Abstract][Full Text] [Related]
10. Structure-activity relations of leucine derivatives reveal critical moieties for cellular uptake and activation of mTORC1-mediated signaling. Nagamori S; Wiriyasermkul P; Okuda S; Kojima N; Hari Y; Kiyonaka S; Mori Y; Tominaga H; Ohgaki R; Kanai Y Amino Acids; 2016 Apr; 48(4):1045-1058. PubMed ID: 26724922 [TBL] [Abstract][Full Text] [Related]
11. L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery. Puris E; Gynther M; Huttunen J; Auriola S; Huttunen KM Eur J Pharm Sci; 2019 Mar; 129():99-109. PubMed ID: 30625368 [TBL] [Abstract][Full Text] [Related]
12. L-type amino acid transporter 1 (LAT1): a new therapeutic target for canine mammary gland tumour. Fukumoto S; Hanazono K; Komatsu T; Ueno H; Kadosawa T; Iwano H; Uchide T Vet J; 2013 Oct; 198(1):164-9. PubMed ID: 23896327 [TBL] [Abstract][Full Text] [Related]
13. L-Type amino acid transporter 1 as a target for drug delivery. Puris E; Gynther M; Auriola S; Huttunen KM Pharm Res; 2020 May; 37(5):88. PubMed ID: 32377929 [TBL] [Abstract][Full Text] [Related]
14. L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs). Huttunen J; Gynther M; Vellonen KS; Huttunen KM Int J Pharm; 2019 Nov; 571():118714. PubMed ID: 31610281 [TBL] [Abstract][Full Text] [Related]
15. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. Kanai Y Pharmacol Ther; 2022 Feb; 230():107964. PubMed ID: 34390745 [TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1). Kongpracha P; Nagamori S; Wiriyasermkul P; Tanaka Y; Kaneda K; Okuda S; Ohgaki R; Kanai Y J Pharmacol Sci; 2017 Feb; 133(2):96-102. PubMed ID: 28242177 [TBL] [Abstract][Full Text] [Related]
17. Amino acid ester prodrugs conjugated to the α-carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1). Rautio J; Kärkkäinen J; Huttunen KM; Gynther M Eur J Pharm Sci; 2015 Jan; 66():36-40. PubMed ID: 25305508 [TBL] [Abstract][Full Text] [Related]
18. Hemocompatible LAT1-inhibitor can induce apoptosis in cancer cells without affecting brain amino acid homeostasis. Markowicz-Piasecka M; Huttunen J; Montaser A; Huttunen KM Apoptosis; 2020 Jun; 25(5-6):426-440. PubMed ID: 32405891 [TBL] [Abstract][Full Text] [Related]
19. A new treatment for human malignant melanoma targeting L-type amino acid transporter 1 (LAT1): a pilot study in a canine model. Fukumoto S; Hanazono K; Fu DR; Endo Y; Kadosawa T; Iwano H; Uchide T Biochem Biophys Res Commun; 2013 Sep; 439(1):103-8. PubMed ID: 23954667 [TBL] [Abstract][Full Text] [Related]
20. Role of l-Type Amino Acid Transporter 1 at the Inner Blood-Retinal Barrier in the Blood-to-Retina Transport of Gabapentin. Akanuma SI; Yamakoshi A; Sugouchi T; Kubo Y; Hartz AMS; Bauer B; Hosoya KI Mol Pharm; 2018 Jun; 15(6):2327-2337. PubMed ID: 29688723 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]